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Abstract
This article proposes to analyze the formation of biotechnological field bringing actor-network theory’s lens as contribution. 
Based on conclusions of studies developed by Walter Powell and colleagues it was held a research to analyze the diversity 
of institutional relations that are active by hemophilia therapies, the principle of generalized symmetry adopted for actor-
network theory is highlight to identify how socio-technical associations are assembled. Besides the interorganizational 
relations, research’s findings indicate the scientific and technological contents have a significant mediating role to create 
and sustain those connections of knowledge. So, it is emphasized the need of a boarder theoretical discussion to enlarge 
explanations about the dynamics of organizational fields as well as innovation processes.        
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Introduction
The aim of this paper is to analyze the formation of 
biotechnological field. The concept of organizational 
field is the start point to discussion, so this introduction 
situates the emergence of biotechnology and the 
theoretical questions around organizational theory. The 
following section deals with to situate central issues 
from our study, indicating methodological bases for 
data collection and their analysis. And, in the last two 
sections, the first presents data analysis while the second 
is discussed actor-network theory contributions to 
improve the understanding of socio-technical associations 
that configure the field.
According to Marques and Gonçalves Neto (2007), 
biotechnology is one of the oldest areas of knowledge and 
goes back many centuries ago to the manufacture of bread, 
beer and wine. In last century, modern biotechnology is 
emerging from scientific and technological relations in areas 
such as molecular biology, biochemistry, microbiology 
and genetics (Trigueiro, 2002), characterized by a “set 
of enabling technologies that allow to use, change and 
improve living organism or their parts, cells, organelles and 
molecules, to produce products, processes and services 
with economic applications in human and animal health, 
agriculture and environment.” (Judice and Baêta, 2005: 171).
 
In twenty-first century, biotechnology brings promise 
for the future of various technologies in many sectors 
and supply chains, being considered as an activity of high 
innovation, involving a lot of scientific and technological 
organizations beyond those directly linked to production, 
and characterizing an industry based on science.  Its brand 
has a pronounced division of labor between universities, 
research organizations, biotech firms, large corporations, 
etc. that forming a dense network of relations and intensive 
use of knowledge based on technological capabilities. 
(Orsenigo, 2006; Powell, Koput and Smith-Doerr, 1996; 
Powell, 1999; Powell et al. 2002).
A biotechnology revolution had its landmark in 1973 when 
Stanley Cohen, from Stanford University, and Hebert 
Boyer, from University of San Francisco, developed the 
technique of recombinant DNA. This is the basis for genetic 
engineering and the rapid creation of knowledge-based 
firms (biotech firms) during the following years whose 
function was transfer scientific findings to the industry, 
at first. (Coriat, Orsi and Weinstein, 2003; Owen-Smith 
et al. 2002). Also in US, the Bayh-Dole Act (1980), as 
well as expansions of venture capital and other facilities 
for technological transfer have contributed to boom of 
biotech field which was primarily organized by access 
to new knowledge at local spillovers or international 
alliances, having the patents as one important information 
source to signal new process and products. (Niosi, 2003; 
Owen-Smith et al. 2002; Owen-Smith and Powell, 2004).
Niosi (2003) identified this broad scope of 
interorganizational relations or network as a field 
that bears a new institutional framework to support 
biotechnological development, specifically referring to 
the Canadian case. Before, however, in another study 
about US, Powell (1999) inferred that those networks 
(in which partnerships, strategic alliances, and licensing 
agreements take place), highlight the emergence of a field 
characterized by heterogeneity of organizational forms. 
In seventies, such forms were particularly directed to 
scientific laboratories and universities, while in the 
eighties and nineties were extend to large pharmaceutical 
corporations and biotech firms, configuring geographical 
propinquity clusters at San Francisco Area Bay, Boston 
and San Diego, as well as within European regions. 
(Owen-Smith et al. 2002; Owen-Smith and Powell, 2004; 
Porter, Whittington and Powell, 2005; Powell, Packalen 
and Whittington, 2010).
If, on the one hand, Niosi (2003) considers biotech field 
without any reference to the definition of DiMaggio 
and Powell (1991), on the other, Powell (1999) explicitly 
deals with the concept. An organizational field is “those 
organizations that, in aggregate, constitute a recognized 
area of institutional life: key suppliers, resources and 
product consumers, regulatory agencies, and other 
organizations that produce similar services or products.” 
(DiMaggio and Powell, 1991: 64), so that the rationalization 
of organizations stems from the rationalization of 
organizational environments (Meyer, 2008), or, as Scott 
(1994) points out, field is a community of organizations that 
participate in the same meaning system, define by similar 
symbolic processes, and subject to common regulatory 
processes. And the structure of an organizational field is 
identified by increase in the extent of interaction among 
organizations in the field; the emergence of sharply 
defined interorganizational structures of domination and 
patterns of coalition; an increase in the information load 
with which organizations in a field must contend; and the 
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development of mutual awareness among participants in 
a set of organizations that they are involved in a common 
enterprise. (DiMaggio and Powell, 1991: 65).
As Scott (1995) also suggests a field is institutionalized 
when a same institutional logical extend and directs the 
activities from an increase in the structural equivalence of all 
organizations by homogenization of routines and practices.
Powell et al. (2005: 1145) note that in the late nineties, 
“the biotech field gained the coherence, and the pattern 
of reliance on collaboration proliferated, institutions 
emerged to both facilitate and monitor the process”, 
implicitly indicating the normalization of routines 
and practices which, however, are recalcitrant to 
homogenization. Thus, “the diversity of institutional 
forms – public, private, and non-profit – that are active in 
the field is located in different selection environments.” 
(Powell et al., 2005: 1190). 
Powell and Colyvas (2008: 287) point out that although 
commercial technological transfer in biotech field became 
institutionalized, also “the variation in responses reflects a 
profound tension between public and private science”. So 
an institutional logic market-oriented prominent within 
biotech clusters since nineties (Porter, Whittington and 
Powell, 2005; Owen-Smith and Powell, 2004) could co-
exist with an open science logic widespread by public 
and non-profit research organizations, such as research 
institutes and universities, or by networks of researchers 
on the basis of collaborative research inherent to sciences 
and their invisible colleges. (Whittington, Owen-Smith 
and Powell, 2009). 
As Owen-Smith and Powell (2008: 600) highlight the fields 
“are shaped by networks, which condition the formation 
of relationships and help establish their consequences” 
and disparate meanings could to represent a multiply of 
social embeddedness that is “the joint outcome of both 
networks and institutions”.  Whittington, Owen-Smith 
and Powell (2009) justify the intensive flux of knowledge, 
that characterizing biotech field, is also influences by 
multiple types of affiliation and the “pipelines” given 
the geographical propinquity. Explicitly the biotech field 
involves the circularity of social, economic, scientific and 
technological issues. And, because of this, the analysis 
of relations between networks and institutions needs 
to adopt “lens that emphasizes comparative dynamics.” 
(Owen-Smith and Powell, 2008: 617). 
In order to improve the dynamic analyses of organizational 
fields, we propose the lens of actor-network theory 
(ANT). Originally a “reflection about science”, ANT 
puts on question “the general problem of social order” 
through a “dogged scrutiny of traditional dichotomies” 
such as “nature-society, subject-object and macro-micro”. 
(Domènech and Tirado, 1998: 13). And, according Holt 
(2008: 23), “ANT gains much of its notoriety through 
advocating a socio-philosophical approach in which human 
and non-human, social and technical factors are brought 
together in the same analytical view.”
The basis of ANT is the generalized principle of symmetry 
that was adopted by researches from social studies of 
science as Bruno Latour, Michel Callon and John Law. This 
principle allows not adopt artificial divisions so that the 
explanation is given by the mediation of elements before 
separate at poles from nature or from society. (Callon, 
1989; Latour, 1994; 2000; Latour and Woolgar, 1997). In 
this sense, ANT is concerned to analysis the association 
of heterogeneous materials (Law and Hetherington, 
2000), human and non-human, and especially how they 
are associated to produce socio-technical collectives. 
(Latour, 2004; 2005). “The concept of the ‘actor-network 
was introduced to describe such associations” (Callon, 
Law and Rip, 1986: 105), therefore ANT enables to 
study assembling and stabilizations of those associations, 
highlights the mechanism through which social and 
natural world gradually will be shape, mapping out the 
accumulation of heterogeneous materialities that become 
more durable and spread out at time and space (Callon, 
1986; Latour, 2000; 2001; 2005; Law, 1999). 
Methodological Issues
The motivation of this study was based on the results 
of a research about the network of information on 
hemotherapy, developed by Fernandes (2010). Fernandes’ 
study aimed to describe the socio-technical associations, 
using scientometrics and social network analysis as 
methodological resources to analyze a sample of 137 from 
a universe of 909 patents collected in the United States 
Patent and Trademark Office (USPTO) that were registered 
between the seventies and early twenty-first century. 
First, this research was based on the graph resulting from 
Fernandes’ study to identify the composition of relational 
structure between patents in twenty-first century. It was 
identified seven core patents. Then, we consulted 
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annexes data from Fernandes’ document to identify all 
who were assignees of those patents, identifying many 
organizations indicated in researches of Walter R. Powell 
and his colleagues as those that constitute regional biotech 
clusters in US.
This led us to question whether the clusters of hemophilia 
had similar characteristics to those identified by Powell. 
Also to question whether was possible to analyze the 
structuring of biotechnological field and to compare with 
Powell’s conclusions. 
This research has an exploratory and descriptive nature, 
however. Therefore, differs to researches developed 
by Powell and his colleagues that had an explanatory 
character, using a broad database collected from Bioscan, 
over the period 1988-2004 (see Owen-Smith and Powell, 
2004 and Powell, Packalen and Whittington, 2010). Our 
date cover the period from 1981 to 2005 of document-
patents that were collected from database of United 
States Patent and Trademark Office (USPTO).
Cluster n. Assignees Organization Principal Inventor Cities Registered
Year
1 Do not exist Harvey Pollard - 2002
2 Cell Genesys Inc. Richard Snyder South San Francisco, 
CA
2004
3 Chiron Corp. Douglas Jolly Emeryville, CA 2004 
4 Virginia Tech Intellectual Prop. 
and Department of Health from 
USA government
Oral Alpan Blacksburg, VA and 
Washington, DC 
2007
5 Center for Blood Research Denise Wagner Boston, MA 2008
6 American Red Cross and Virginia 
Tech Intellectual Prop. 




We analyzed the seven core document-patent contents, 
and it was ruled out one of them, because was registered 
a similar method by same inventors, Harvey and Bette 
Pollard. Thus, in this study were considered six core 
patents, beyond those directly quoted by them, totalizing 
52 documents. Also, we considered 41 documents, 
quoted by one of those cited patent, because its contents 
highlighted enrollments in three of six core patents. 
So that, an amounted of 93 documents were analyzed, 
and 31 of them have not appeared in Fernandes’ sample. 
On each document were collected the following data: 
the technology registered; inventors’ names; assignee 
organizations; city and country of each organization; filing 
data; register date; government interest (when there), 
besides their abstracts and scientific contents.
For data analysis each of the six core patents, and those 
quoted by them, were regarded as a cluster. The Table 1 
below presents a synthesis of each cluster, identifying the 
organizations that registered the patent and its host city, 
also state the name of the principal inventor of research 
team, and registered year.
Table 1 – Main Clusters of Hemophilia
We first examined the set of organizations and inventors of 
each cluster, also its location, in order to identify whether 
it was possible to establish some relations with Powell’s 
findings, related institutional logic and geographical 
propinquity, the two main elements that characterize the 
field of biotechnology seconded by him. However, relations 
between organizations and between inventors were not 
clearly identified. Evidently it was taken into account 
that the average of 15 patents in each cluster cannot 
be comparable to 462 organizations that constituted 
the sample of those studies, but when we consider the 
technologies registered could be identified some relations. 
Since it was not possible to do an analysis considering only 
social actors, this research adopted the principle of ge-
neralized symmetry from actor-network theory (Callon, 
1986; Latour, 1994; 2000; 2001; 2004) taking into account 
both human (organizations and inventors) and non-human 
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(technologies) actors to analyze associations within clus-
ters. With this lens was possible concentrate attention on 
circulation of actors, following those that “modify a state 
of affairs by making difference” (Latour, 2005) and look to 
their “way of performing” (Law, 1999) into each cluster.
It was necessary to consider the content of each 
document-patent by adopting the concept of 
“inscription” as an organizing principle of the scientific 
facts, as Latour and Woolgar (1997), and analyzing the 
networks of problematisation as proposed by Callon, 
Law and Rip (1986) to trace the dynamic of science 
and technology, recognizing that “a patent application 
is a compromise between different strategies of 
enrollment.” (Rip, 1986: 92). Therefore, it was necessary 
to understand a little more about gene therapy for the 
hemophilias consulting other documents, one in special 
published by World Federation of Hemophilia whose 
authors are David Lilicrap and Arthur R. Thompson.
Lilicrap and Thompson (2008: 1) begin by explaining that 
“for a patient with hemophilia, gene therapy would allow 
continuous synthesis of a normal protein to correct the 
deficiency state in vivo.”  First, however, we must clarify 
the types of this hereditary genetic disease that cripples 
the body to control bleeding (hemorrhagic diathesis). 
Hemophilia A is the most frequently and refers to a sex-
linked recessive deficiency of coagulation factor VIII and 
accounts for 85-90% of cases reported internationally, 
according to World Health Organization (WHO). 
Hemophilia B is caused by mutation in the factor IX gene, 
also known as Christmas disease. While Von Willebrand 
disease is hereditary and caused by a fall or a dysfunction 
of the protein called von Willerbrand factor affecting 
around 2% of world population.
Traditionally, the treatment for hemophilia involves 
plasma transfusions to replace the deficient clotting 
factor that are found in various blood products to ensure 
the homeostasis. Thus, there is a concern for the safety 
of plasma, as well as the quality of its fractionation. (see 
WFH, 2008). Also, the patients with hemophilia could 
develop inhibitors that fight proteins contained in those 
products requiring specific treatments. 
Hemophilia has not cure, but adding a functional gene to a 
cell could be comparable as a cure. Lillicrap and Thompson 
(2008) distinguish therapy that uses modify somatic cells 
of a host from other experimental approaches that lead 
to transgenic animal as well as those directed to gene 
transfer and gene repair. According to them “the transfer 
of DNA into cells for gene therapy is accomplished by 
transduction, a controlled process that is mediated by 
vector or vehicles that attach to a cell surface and facilitate 
entry into the cell.” (Lillicrap and Thompson, 2008: 2).
The vectors for transduction commonly derive from 
viral nucleic acid backbone and the preclinical studies to 
gene therapy are concentrated in three types of them: 
retroviral vector; adenoviral vector and adeno-associated 
viral (AAV) vector. Also researchers are directed to 
non-viral vectors, alternative type cells and gene repair. 
Nowadays vector systems are capable to deliver factor IX 
or VIII cDNAs to host cells and express clotting factors in 
vivo efficiently as well as these factors can be expressed 
and secreted through the milk of a transgenic mammal, so 
therapeutic trials in human patients are being tested. Thus, 
hemophilia represents “a leading candidate condition for 
the successful application of gene therapy”, and despite 
challenges of the development of safe, “effective methods 
to provide a “cure” for hemophilia remain feasible.” 
(Lillicrap and Thompson, 2008: 9).
Clusters Analysis 
In this section are described each cluster. Also an 
analytical synthesis is presented considering assignees 
organizations, types of therapies, geographic location and 
organizational forms.
The Cluster 1 is characterized by the enrollments of an 
artificial gland, a bioartificial pancreas, an extracorporeal 
reactor, a dried and sterilized gamma-globulin-fixed 
column, as well as implant techniques and therapies, and 
an apparatus for therapeutically treating immunological 
disorders and disease states. Those techniques was 
developed by universities of Massachusetts, Toledo and 
Brown, pharmaceutical multinational company, Merck, 
and other companies such as Industrikontakt from 
Scandinavian countries, and Asahi Kasei, a chemical 
company from Japan. All of them serve to Harvey and 
Bette Pollard develop methods for treating hemophilia A 
and B and AIDS, and register a patent that does not have 
any assignee, but represents US government’s interest. 
However, in this cluster is not possible to identify any 
mediation that assembles the patents with work of others 
inventors and institutions. So that the Pollards were 
limited to the laboratory boundaries, and do not 
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mobilized a network as vehicle of translation to extend 
and trace new paths and entities, as suggests by ANT. 
At same time, this method is not specifically directed to 
protein or gene therapies, before is related to a treatment 
with a permeable membrane.   
Cluster 2 refers to recombinant adeno-associated 
viral (AAV) vector for gene therapy of hemophilia A 
developed by Cell Genesys who belongs to aggregate 
of the biotech firms located at San Francisco Bay Area. 
The set of patents involve the Universities of Florida and 
Pennsylvania, the Children’s Hospital of Philadelphia, the 
biotech firm Avigen, also located at San Francisco Bay 
Area (with two patents), and one no assignee patent 
that have a team of five inventors from North Carolina, 
Maryland and Tennessee. Thus, recombinant AAV vectors 
are combined to administering genes in animal muscle, to 
isolate DNA encoding Factor IX, for introduce foreign 
DNA in mammalian cells and constructing a hybrid gene 
vector, and to express vectors in mammalian genes as 
well as human cells, delivering nucleic acid which result in 
the production biologically active Factor VIII in vivo, what 
enabling Cell Genesys provides methods and materials 
for expressing a polypeptide with factor VIII activity 
comprising administering an rAAV vector through its 
recombinant, standing out a partnership between biotech 
firms that does not enroll other organizations from San 
Francisco Bay Area, however.  Geographical propinquity 
is not exactly what characterizes this cluster, which 
assembles firms, and universities, inventors, the children’s 
hospital to produce translations about AAV vectors, and 
stabilize a gene therapy to hemophilia A.
Another biotech firm from San Francisco Bay Area, Chiron 
registers methods for administration of recombinant 
gene delivery vehicles for treatment of hemophilia and 
other disorders, composing Cluster 3. Three patents 
are cited without any assignee, two of them belonging 
to inventors of San Diego and another involving a team 
of British inventors with one from Maryland. The other 
technologies belong to Universities of Michigan and 
California, the Fred Hutchison Cancer Research Center 
from Seattle, and the Alexion, a global biopharmaceutical 
company founded in 1992, from Connecticut. Once 
again it has an enrollment of techniques laid out by 
a set of private, public and non-profit organizations. 
They assemble methods to delivery of proteins by 
catheterization and preserving an infectious recombinant 
virus; DNA constructs for retrovirus packaging cell lines; 
generation, concentration and efficient transfer of VSV-G 
pseudotyped retroviral; genetic alteration to introduction 
of nucleic acid expression particles to construct directing 
the expression of retroviral inhibitor activity of chimeric 
proteins into cells; retroviral vectors produced by 
producer cell lines as in vivo gene delivery vehicles and 
recombinant retroviruses expressing a protein that 
converts a pro-drug into a cytotoxic agent translating 
gene therapy based on retroviral vectors that overcome 
American boundaries.
In Cluster 4 are assembled techniques registered by 
American National Red Cross, Virginia Polytechnic 
Institute & State University, American Red Cross, Virginia 
Tech Intellectual Properties, the Japanese pharmaceutical 
company, Dainippon, the biotech firm Biogen, the Shire 
Laboratorie (belonging Boston region), the biotech 
firm Avigen (San Francisco region), and the British PPL 
Therapeutic, to stabilize a oral treatment of hemophilia 
registered by the Secretary of the Department of Health 
and Human Service of US government and Virginia Tech 
Intellectual Properties. The Japanese company contributes 
with a pharmaceutical composition for oral administration 
containing coagulation factor VIII or IX which is 
assembled in translations to production of recombinant 
proteins in mammals’ milk, as well as five transgenic 
mammals to expression of human protein C in mammary 
tissue that incorporate DNA, also to expression human 
coagulation of factor VIII, to produce factor IX and DNA 
sequences with modified splice sites, to active factor IX in 
mammary tissue and of milk, and to expression of human 
coagulation factor VIII and von Willerbrand factor beside 
an AAV vector for expression of factor VIII by target 
cells and an oral induction of tolerance to parenterally 
administered non-autologous polypeptides. We have 
here an example of experimental approaches that lead 
to transgenic animal that are aimed to “generating female 
animals such as pigs that secrete human factors VIII or 
IX in their milk”, as assigned by Lillicrap and Thompson 
(2008: 2), that also highlight one significant partnership 
between the American National Red Cross and Virginia 
Tech Intellectual Properties of Virginia Tech University to 
produce these socio-technical associations. 
Cluster 5 involves two pharmaceutical compositions 
containing the P-selectin ligand protein and methods 
of treating inflammatory disease states characterized 
by P-selectin- and E-selectin-mediated intercellular 
adhesion registered by biotech firm Genetics Institute, 
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from Cambridge (belonging Boston region), that are 
translated with two other techniques developed by same 
firm, specifically a nucleic acid encoding a novel P-selectin 
ligand protein and a method of inhibiting P-selectin ligand 
activity. Also two patents of biotech firm Cytel, from San 
Diego (belonging San Diego region), related to antibodies 
to P-selectin and a method for detecting the presence of 
P-selectin, and another registered by biotech firm Protein 
Design, from Mountain View (San Francisco region), 
related to cross-reacting monoclonal antibodies specific 
for E- and P-selectin and others techniques registered by 
Universities of Oklahoma and California, as well as New 
England Medical Center Hospital from Boston concern to 
a modulation of inflammatory responses by administration 
of GMP-140 or antibody to GMP-140; a plasma and 
polymer containing surgical homeostatic adhesives; an 
inhibition of L-selectin and P-selectin mediated binding 
using heparin and a method of inhibiting PADGEM-
mediated or ELAM-1 mediated leukocyte adhesion using; 
and an inhibitor comprising a Le.sup.x core component, 
including too a method for fabricating a high voltage MOS 
device developed by United Microelectronics corporation 
from Taiwan, are all enrolled in this cluster, that do not 
properly represent a biotechnology. Here also do not 
identify any significant geographical propinquity laid out 
by Powell and colleagues, so that the network center is 
located in the translations of P-selectin for the Centre 
for Blood Research, from Boston, to develop methods 
of treating hemophilia or Von Willebrand disease with 
P-selectin, indicating their concern over the development 
of protein inhibitor to treatments with plasma.
Finally, in Cluster 6 methods of producing a substance 
comprising a peptide, involves incorporating a DNA 
sequence coding for the peptide into a gene of a 
mammal (such as a sheep) coding for a milk developed 
by British biotech firms, Pharmaceutical Proteins and PPL 
Therapeutics, are assembled with recombinants techniques 
to express in mammary tissues of transgenic mammals 
a heterologous polypeptide and human protein C both 
registered by American Red Cross with partnership of 
the US government - Department of Health and Human 
Services and Virginia Intellectual Property Division 
respectively, as well as the production of recombinant 
proteins in mammals’ milk registered by Biogen, the 
technique to improve factor IX product developed by 
non-profit organization Blood Systems, from Arizona, 
and the factor IX cDNA inserted into an expression 
vector that has the British government agency, National 
Research Development, as assignee. All those translations 
result in a recombinant Factor IX characterized by a 
high percentage of active protein obtained in the milk 
of transgenic animals that incorporate chimeric DNA 
molecules to treat hemophilia registered by American 
Red Cross and Virginia Tech Intellectual Properties. With 
the exception of Blood Systems, all cluster patents quote 
Biogen patent, one of the oldest biotech firms, founded in 
1978 by biologists as Walter Gilter, Nobel price, and other 
researches from Harvard and Massachusetts Institute of 
Technology that belonging Boston region. However, the 
true actors that have a mediation to produce these socio-
technical associations are the transgenic mammal and the 
recombinant product in its milk, registered by Biogen. 
From the above analysis of each cluster, we consider that 
the cluster 1 presented particular characteristics when 
is regarded the method registered, and does not be 
adequate to comparative analysis that will be discussed in 
the next section. Therefore, it was excluded of synthesis 
presents below. 
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Cluster Assignee 
Organization
Hemophilia Therapy Geographic 
Ties
Organizational forms 
2 Cell Genesys Inc. AAV vectors to factor 
expression in hostÕs 
cells
US Biotech firms, universities, 
hospital, and team of inventors 
3 Chiron Corp. Retroviral vectors to 
factor expression in
hostÕs cells 
US-Britain Biotech firm, global 
biopharmaceutical company,
universities, research center and 
team of inventors 
4 Virginia Tech 
Intellectual Prop. and 




secrete human factor in 
their milk  
US-Britain-
Japan
Universities, government agency 
non-profit organization, biotech 
firms, large multinational 
company and laboratory  
5 Center for Blood 
Research
Plasma treatment with 
P-selectin  
US Research center, biotech firms, 
universities and hospital 
6 American Red Cross
and Virginia Tech 
Intellectual Prop. 
Transgenic animals 
secrete human factor in 
their milk  
US-Britain Non-profit organizations, 




Based on these results must now discuss at the first whether 
could be identified a formation of biotechnological field, 
or more properly an organizational field of hemophilia. 
When we consider the characteristics defined by 
DiMaggio and Powell (1991) for identifying this structure 
can be seen that there was an increase in information 
load over the years. For example, between the eighties 
and nineties has had an increase of 400% in the number 
of registered patents at our sample. Also can be identified 
a common enterprise to the development of hemophilia 
treatments referring to gene therapy or those related to 
improvements in the treatments with plasma that increased 
the extent of interaction, basically founded on technical 
and scientific contents, do not limited to organizations, 
but including too inventors and mainly techniques. 
However, we cannot identify “the emergence of sharply 
defined interorganizational structures of domination and 
patterns of coalition” (DiMaggio and Powell, 1991: 64). 
As we highlight the interactions were not limited to 
interorganizational relations, the translations made 
possible the stabilization of relations that did not refers 
specifically to a coalition or domination, but the sharing 
of contents. Such interactions are related to human and 
non-human associations to “tell particular stories about 
particular relations”, as suggests Law (2008: 143).
Table 2 – Synthesis of cluster analysis
This leading us to question and discuss what characterizes 
such interactions within the field. First, despite many 
organizations belong regional clusters as Powell and 
colleagues identified (see Powell, Packalen and Whittington, 
2010; Whittington, Owen-Smith and Powell, 2009; Porter, 
Whittington and Powell, 2005; Owen-Smith and Powell, 
2004), a geographical propinquity typically linking the 
organizations of Boston region, or San Francisco Bay Area 
region, or San Diego region, cannot be characterized, 
because, there were partnerships between organizations 
from several regions of US.  
Considering the geographical propinquity it was only 
possible to identify the extent of interactions within 
the borders of US or beyond. Thus, we cannot consider 
the geographical propinquity as an explanation, only 
that the scientific contents are stretched across local 
and regional borders, and enroll it through the national 
and international boundaries. Therefore innovations in 
the treatment with p-selectin and gene transfer using 
AAV vectors are restrict to US borders, while the gene 
transfer by retroviral vectors or transgenic mammals 
occur through partnerships especially between American 
and British organizations. 
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At the same time, if there is a same institutional logic does 
not concern a structural equivalence of organizations or 
a same symbolic meanings system, as suggested by Scott 
(1994, 1995). Such logic must be considered in relation 
to scientific contents. This involves questions related to 
routines and practices, because both facts and values 
should be symmetrically considered, especially when 
we see collective formations, as proposes Latour (2004; 
2005). So that, the collective “don’t mean an action carried 
over by homogeneous social forces, but, on contrary, 
an action that collects different types of force woven 
together because they are different.” (Latour, 2005: 74).
 
In each cluster it was identified the diversity of institutional 
forms – private, public, and non-profit – as Powell et al. 
(2005) point out. A constant presence of universities and 
biotech firms was mixed to research centers, hospitals, 
multinational companies, non-profit organizations, 
laboratories, team of inventors, and government agencies 
differently.  They are not active in the field in different 
selection environments, however, as Powell et al. (2005) 
propose. They are active in the field because a non-human 
actor as one transgenic mammal enrolls them to mobilize 
their resources, for example. So, transgenic mammals, 
p-selectin proteins, and AAV or retroviral vectors are those 
that act as actor-networks, constituting in the obligatory 
centers of passage to assemble different organizational 
forms, producing associations and transformations.  
With this lens private and public tensions, suggested by 
Powell and Colyvas (2008), are not so evident, because an 
open science or a market-oriented logical is the effect not 
the cause of translations that produce the networks. As a 
consequence we could to say that there is no specifically 
“multiply of social embeddedness”, as Owen-Smith and 
Powell (2008) point out, but a multiply of translations that 
joint networks and institutions. So that the translations 
shape relationships that are temporally stabilize, and 
result in therapies for hemophilia. 
Thus, it was possible to follow the circularity of social, 
economic, scientific and technological issues in the 
biotechnological field. It was possible to accompany 
actors’ translations through their fluid socio-technical 
associations where non-human actors performing as 
mediators. They were essential to assembling human 
actors, and to understanding how contents are enrolled by 
successive transformations, making knowledge circulate. 
So that, the core question in studies of field formation 
is not only to concern with “how a collection of 
organizations cohere into a community, engaged in 
common activities and subject to similar reputational 
and regulatory processes”, as propose Powell, Packalen 
and Whittington (2010). However, we agree with these 
authors that a crucial role to create and sustain those 
interorganizational relations is pervaded for connections 
mediated through “anchor tenants”, mainly when we 
see beyond social interactions and include scientific 
and technological contents. These contents are those 
who actually signed non-humans actors, as transgenic 
mammals, proteins, vectors for transduction, and so on, 
to provide some that Powell, Packalen and Whittington 
(2010) award only the organizations: “multiple means for 
information exchange, varied organizational strategies, 
and divergent criteria for success.”
Although, ANT highlights the mechanism through which 
social and natural world takes shape (Callon, 1986), 
identifying how socio-technical associations were been 
made, it is much more on descriptive than explanatory 
foundational terms. (Law, 2008). Once innovation systems 
are characterized as aggregated of institutional forms and 
collective efforts within which science, technology, firms, 
education and political organizations have interactions 
(Edquist, 1997; Freeman, 1987), we suggest that future 
studies should emphasize a broader theoretical discussion 
between ANT and Institutional Theory as well as 
Evolutionary Theory to analyze dynamics of organizational 
field and innovation, especially when knowledge and 
learning must be explain as strategic factors, as proposes 
Lundvall (2005). 
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